Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs.

about

Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs.

Item

http://www.wikidata.org/entity/Q47821070

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Early health technology assess ...... ample in cardiovascular drugs.

@en

Early health technology assess ...... ample in cardiovascular drugs.

@nl

type

Item

label

Early health technology assess ...... ample in cardiovascular drugs.

@en

Early health technology assess ...... ample in cardiovascular drugs.

@nl

prefLabel

Early health technology assess ...... ample in cardiovascular drugs.

@en

Early health technology assess ...... ample in cardiovascular drugs.

@nl

P1476

Early health technology assess ...... xample in cardiovascular drugs

@en

P2093

Anke H Maitland-van der Zee

http://www.w3.org/2001/XMLSchema#string

Anke M Hövels

http://www.w3.org/2001/XMLSchema#string

Anthonius de Boer

http://www.w3.org/2001/XMLSchema#string

Ekaterina V Baranova

http://www.w3.org/2001/XMLSchema#string

Joost W Geenen

http://www.w3.org/2001/XMLSchema#string

Rick A Vreman

http://www.w3.org/2001/XMLSchema#string

P2860

Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Angiotensin-converting enzyme inhibitors and angioedema.

Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information.

Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.

Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Ten years of next-generation sequencing technology.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.

Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors

Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema.

P304

1143-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS-2017-0063

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Folkert W. Asselbergs

Colin Palmer

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28745583

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics